721 related articles for article (PubMed ID: 15477656)
1. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
3. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cells as targets for immunotherapy of autoimmune diseases.
Van Kaer L
Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.
Singh AK; Wilson MT; Hong S; Olivares-Villagómez D; Du C; Stanic AK; Joyce S; Sriram S; Koezuka Y; Van Kaer L
J Exp Med; 2001 Dec; 194(12):1801-11. PubMed ID: 11748281
[TBL] [Abstract][Full Text] [Related]
6. BCR targeting of biotin-{alpha}-galactosylceramide leads to enhanced presentation on CD1d and requires transport of BCR to CD1d-containing endocytic compartments.
Lang GA; Illarionov PA; Glatman-Freedman A; Besra GS; Lang ML
Int Immunol; 2005 Jul; 17(7):899-908. PubMed ID: 15967785
[TBL] [Abstract][Full Text] [Related]
7. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.
Hong S; Scherer DC; Singh N; Mendiratta SK; Serizawa I; Koezuka Y; Van Kaer L
Immunol Rev; 1999 Jun; 169():31-44. PubMed ID: 10450506
[TBL] [Abstract][Full Text] [Related]
8. CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.
Ilyinskii PO; Wang R; Balk SP; Exley MA
J Virol; 2006 Jul; 80(14):7146-58. PubMed ID: 16809320
[TBL] [Abstract][Full Text] [Related]
9. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
10. Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts.
Lang GA; Maltsev SD; Besra GS; Lang ML
Immunology; 2004 Jul; 112(3):386-96. PubMed ID: 15196206
[TBL] [Abstract][Full Text] [Related]
11. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes.
Nishimura T; Kitamura H; Iwakabe K; Yahata T; Ohta A; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nakui M; Sekimoto M; Koda T
Int Immunol; 2000 Jul; 12(7):987-94. PubMed ID: 10882410
[TBL] [Abstract][Full Text] [Related]
12. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells.
Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA
Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291
[TBL] [Abstract][Full Text] [Related]
13. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
14. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
[TBL] [Abstract][Full Text] [Related]
15. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
16. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner.
Lang GA; Exley MA; Lang ML
Immunology; 2006 Sep; 119(1):116-25. PubMed ID: 16792697
[TBL] [Abstract][Full Text] [Related]
17. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
[TBL] [Abstract][Full Text] [Related]
18. Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells.
East JE; Kennedy AJ; Webb TJ
Med Res Rev; 2014 Jan; 34(1):45-76. PubMed ID: 23239102
[TBL] [Abstract][Full Text] [Related]
19. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.
Borg NA; Wun KS; Kjer-Nielsen L; Wilce MC; Pellicci DG; Koh R; Besra GS; Bharadwaj M; Godfrey DI; McCluskey J; Rossjohn J
Nature; 2007 Jul; 448(7149):44-9. PubMed ID: 17581592
[TBL] [Abstract][Full Text] [Related]
20. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
